Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
about
Treatment of Cancer Pain by Targeting CytokinesBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisInflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysisUtilizing regulatory T cells against rheumatoid arthritisBlocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statementPathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus ErythematosusFunctional IL6R 358Ala allele impairs classical IL-6 receptor signaling and influences risk of diverse inflammatory diseasesIL-6 receptor antagonist as adjunctive therapy with clotting factor replacement to protect against bleeding-induced arthropathy in hemophiliaThe mechanisms of up-regulation of dendritic cell activity by oxidative stressEculizumab hepatotoxicity in pediatric aHUS.Low levels of vitamin D in neuromyelitis optica spectrum disorder: association with disease disability.Cytokines are both villains and potential therapeutic targets in thyroid-associated ophthalmopathy: From bench to bedside.Influences of IL-6R antibody on PMMA bone cement-mediated expression of OPG and RANKL in synovial fibroblasts.Intravenous laser blood irradiation and tocilizumab in a patient with juvenile arthritisComparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice.Differential expression of pro-inflammatory cytokines IL-15Ralpha, IL-15, IL-6 and TNFalpha in synovial fluid from rheumatoid arthritis patients.Efficacy and safety of tocilizumab in patients with polyarticular-course juvenile idiopathic arthritis: results from a phase 3, randomised, double-blind withdrawal trial.A store-operated calcium channel inhibitor attenuates collagen-induced arthritis.Inhibition of the autocrine IL-6-JAK2-STAT3-calprotectin axis as targeted therapy for HR-/HER2+ breast cancers.Interleukin 6 blockage-induced neutropenia in a patient with rheumatoid arthritis and resolved hepatitis BCurrent perspectives on tocilizumab for the treatment of rheumatoid arthritis: a reviewRecent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.EGFR inhibition induces proinflammatory cytokines via NOX4 in HNSCC.Intracellular Signaling Pathways in Rheumatoid ArthritisTocilizumab in the treatment of rheumatoid arthritis and beyond.The impact of infection and tissue damage in solid-organ transplantation.Novel monoclonal antibodies for therapy of multiple sclerosis.Emerging therapies for noninfectious uveitis: what may be coming to the clinicsSafety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.Monoclonal antibody therapy in multiple sclerosis: critical appraisal and new perspectives.Molecular targets on B-cells to prevent and treat antibody-mediated rejection in organ transplantation. Present and Future.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Pain in rheumatoid arthritis: models and mechanisms.Evaluation of Anti-inflammatory Effects of Steroids and Arthritis-Related Biotherapies in an In Vitro Coculture Model with Immune Cells and Synoviocytes.[Secondary immunodeficiency in rheumatological diseases].A phase II randomized study of subcutaneous ixekizumab, an anti-interleukin-17 monoclonal antibody, in rheumatoid arthritis patients who were naive to biologic agents or had an inadequate response to tumor necrosis factor inhibitors.Disentangling the effects of tocilizumab on neutrophil survival and function.Profile of tocilizumab and its potential in the treatment of giant cell arteritis.Prevention of ovarian hyperstimulation syndrome in a rat model: comparison of the efficacy of tocilizumab with that of ranibizumab, cabergoline, and a gonadotropin-releasing hormone antagonist.A Humanized Anti-Interleukin 6 Receptor Monoclonal Antibody, Tocilizumab, for the Treatment of Endometriosis in a Rat Model.
P2860
Q26779917-53E3EB6A-D85B-4A6A-B662-DF01ED56B7F6Q26852235-20AC26BA-A765-4346-9D98-6061AF4F93FDQ27001736-91BB2DFF-AB5B-4D80-B5FA-ACB15FE4C8E0Q27009990-0A974CE4-37A2-4F66-842E-912D1236A9ACQ27021115-DE0F30CF-A36D-4324-821B-4119229D92E8Q28088753-981BE80B-2001-4838-9E43-0965A2A6042EQ30419941-860B7984-5998-4EEB-9114-746DA7A7D0BCQ30439206-0EC18250-972F-4D01-8BB7-C49774725FA8Q30583882-98C577B1-4C75-466B-9467-C5D8932C24B5Q33418797-96CD6E8D-68A7-4038-98B3-4BBE771B8EF1Q34166367-8666A2EC-E4F0-49E0-A6DD-8FF64FB14544Q34763844-3156FE4D-5E0D-4666-B056-62F6E7E0605AQ35142150-3525FB80-A3E3-4504-8253-BD2FD454D4CDQ35143297-AEBED318-7EFB-45A6-A98C-46B7295FB13EQ35143956-2E0FF1CE-768C-4A09-B636-63ECADFE7BABQ35176993-9969757C-C919-4FDA-99E8-5F37CE0102D2Q35605487-AFAA0575-64AF-488C-8BA4-AF2D4AD4FAAAQ35692995-D142CF43-81EE-41C6-B33C-2553EFF03740Q35952745-53CA972D-8F7B-49D4-93AE-540494F7351BQ36842361-B0CC1C11-5412-4D6F-9C82-5FE8DA2EBF07Q36996859-FE34E291-F2AC-4CA6-A4AE-B864999CEE69Q37019872-F579144E-0DF7-4730-B858-FDA40CCD613CQ37407594-7C002251-F985-4A23-A0B6-732CDFC3B158Q37626617-6509F993-17E9-4AAA-BB5D-2F4DBCBEB600Q37682799-29DA116E-0B60-4BFD-A16B-63FCD4CC42B7Q38013050-CABBCA6D-61D2-4C02-88F0-8053A3A4D5F6Q38191996-D560F9C7-FD1B-4608-B3E6-6616A6D2ED9FQ38215514-43D73140-5F11-424F-8FB7-7162D10CE88FQ38305522-85DD781B-B365-4D2F-B293-59176B709C13Q38364547-3382C33D-55E2-45AC-A84F-BE53C466B83BQ38676578-78D4F756-47AB-4576-BE15-1C283706365DQ38745066-170FC8EA-F4B8-4DBA-B666-8AFD15A9C5E6Q38810372-29EDDABE-25BF-41FC-8A94-274F03E328FEQ41908486-74CB7C12-DAD3-4BC5-9EA5-6EDE97DC556DQ44975901-620207E2-959C-4DA4-A5C7-77E70E2781D6Q46483294-8C181216-6DB5-41E3-ABED-BAABEC488021Q48044670-F225D681-8C49-4E0A-AEF6-025C2CBE5C88Q49215677-22B2F1F1-CEA6-46A1-8085-2CFBB424D73CQ50935781-8FC7B53E-131D-49DC-953A-66BADC2BF54DQ50960074-5290CC42-3CFF-4D80-B847-A16AE5B5BD2D
P2860
Systematic review of tocilizumab for rheumatoid arthritis: a new biologic agent targeting the interleukin-6 receptor.
description
2012 nî lūn-bûn
@nan
2012 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի մարտին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
Systematic review of tocilizum ...... ng the interleukin-6 receptor.
@ast
Systematic review of tocilizum ...... ng the interleukin-6 receptor.
@en
type
label
Systematic review of tocilizum ...... ng the interleukin-6 receptor.
@ast
Systematic review of tocilizum ...... ng the interleukin-6 receptor.
@en
prefLabel
Systematic review of tocilizum ...... ng the interleukin-6 receptor.
@ast
Systematic review of tocilizum ...... ng the interleukin-6 receptor.
@en
P2860
P1476
Systematic review of tocilizum ...... ng the interleukin-6 receptor.
@en
P2093
Jeffrey R Curtis
P2860
P304
788-802.e3
P356
10.1016/J.CLINTHERA.2012.02.014
P577
2012-03-22T00:00:00Z